Amid struggling sales, Takeda's CEO goes all in on globalization — 5 key notes

Takeda CEO Christophe Weber reaffirmed the company's commitment to globalizing its brand and products amid struggling fiscal year 2017 sales, CNBC reports.

Here's what you should know:

1. Mr. Weber said Takeda's growth will come from global product launches instead of smaller regional launches.

2. Mr. Weber stressed the importance of pipeline research. He said the company is focused on developing medicine with "high innovation potential."

3. Takeda's business is focused in three specialties: gastroenterology, oncology and the central nervous system.

4. Mr. Weber was appointed as Takeda's first non-Japanese CEO, and Takeda's board appointed him with the intent of increasing profits. The company's fiscal year 2017 forecast predicts Takeda will post a 15.5 percent increase in profits, approximately $1.65 billion. Despite the increase, Takeda's estimate is below analyst estimates.

5. Mr. Weber said the foundation for a fiscal turnaround is already present. He said to CNBC, "We have done a lot on many fronts: on the commercial front, on the R&D, on the manufacturing. I will say that we have done the heavy lifting of the transformation and we are starting now to see the result, which is nice."

More articles on gastroenterology:
What 15 healthcare practices pay their gastroenterologists — $458k is #1
Gastroenterologists, payers possibly thwarting biosimilar adaptation — 4 key notes
'Relentless dedication to IBD care' — How 3 GI leaders will use their Sherman Prizes to enhance IBD, Crohn's treatment

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months